A
Alexander Y. Andreev-Drakhlin
Researcher at Broad Institute
Publications - 2
Citations - 1815
Alexander Y. Andreev-Drakhlin is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 938 citations.
Papers
More filters
Journal ArticleDOI
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi,Franklin W. Huang,Franklin W. Huang,Franklin W. Huang,Judit Jané-Valbuena,Judit Jané-Valbuena,Gregory V. Kryukov,Christopher Lo,E. Robert McDonald,Jordi Barretina,Ellen Gelfand,Craig M. Bielski,Haoxin Li,Haoxin Li,Kevin Hu,Alexander Y. Andreev-Drakhlin,Jaegil Kim,Julian M. Hess,Brian J. Haas,François Aguet,Barbara A. Weir,Michael V. Rothberg,Brenton R. Paolella,Michael S. Lawrence,Rehan Akbani,Yiling Lu,Hong L. Tiv,Prafulla C. Gokhale,Antoine de Weck,Ali Amin Mansour,Coyin Oh,Juliann Shih,Kevin Hadi,Yanay Rosen,Jonathan Bistline,Kavitha Venkatesan,Anupama Reddy,Dmitriy Sonkin,Dmitriy Sonkin,Manway Liu,Joseph Lehar,Joshua M. Korn,Dale Porter,Michael D. Jones,Javad Golji,Giordano Caponigro,Jordan E. Taylor,Caitlin M. Dunning,Amanda L. Creech,Allison Warren,James M. McFarland,Mahdi Zamanighomi,Audrey Kauffmann,Nicolas Stransky,Marcin Imielinski,Yosef E. Maruvka,Yosef E. Maruvka,Andrew D. Cherniack,Andrew D. Cherniack,Aviad Tsherniak,Francisca Vazquez,Jacob D. Jaffe,Andrew A. Lane,David M. Weinstock,Cory M. Johannessen,Michael Morrissey,Frank Stegmeier,Robert Schlegel,William C. Hahn,William C. Hahn,Gad Getz,Gordon B. Mills,Jesse S. Boehm,Todd R. Golub,Todd R. Golub,Todd R. Golub,Levi A. Garraway,Levi A. Garraway,William R. Sellers,William R. Sellers +79 more
TL;DR: The original Cancer Cell Line Encyclopedia is expanded with deeper characterization of over 1,000 cell lines, including genomic, transcriptomic, and proteomic data, and integration with drug-sensitivity and gene-dependency data, which reveals potential targets for cancer drugs and associated biomarkers.
Journal ArticleDOI
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
Omar Alhalabi,Jianfeng Chen,YuXue Zhang,Yang Lu,Qi Wang,Sumankalai Ramachandran,Rebecca S. S. Tidwell,Guangchun Han,Xinmiao Yan,Jieru Meng,Ruiping Wang,Anh Hoang,Wei-Lien Wang,Jian H. Song,Lidia Lopez,Alexander Y. Andreev-Drakhlin,A Arlene Siefker-Radtke,Xin-qiao Zhang,William F. Benedict,Amishi Yogesh Shah,Jennifer Wang,Pavlos Msaouel,Miao Zhang,Charles C. Guo,Bogdan Czerniak,Carmen Behrens,Luisa M. Solis Soto,Vassiliki A. Papadimitrakopoulou,Jeff Lewis,Waree Rinsurongkawong,Vadeerat Rinsurongkawong,Jack Lee,Jack A. Roth,Stephen G. Swisher,Ignacio I. Wistuba,John V. Heymach,Jing Wang,Matthew Campbell,Eleni Efstathiou,Mark Titus,Christopher J. Logothetis,Thai H. Ho,Jianjun Zhang,Linghua Wang,Jianjun Gao +44 more
TL;DR: In this paper , a single arm phase II trial (NCT02693717) assessed pemetrexed in MTAPdef urothelial carcinoma (UC) with the primary endpoint of overall response rate (ORR).